Stocks

Definium Therapeutics, Inc.

DFTXNASDAQUSDHealthcare

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Ticker
DFTX
Trading on
NASDAQ
ISIN
CA24477V1058
Industry
Biotechnology
Sector
Healthcare
CEO
Robert Barrow
Headquarters
One World Trade Center, New York, NY, United States, 10007
Employees
105
Website
https://definiumtx.com

Metrics

Market cap$4.04B
P/E ratio-
EPS-$2.92
Dividend Yield0.00%
Beta2.21
Forward P/E ratio0
EBIDTA$-166M
Ex dividend date-

Analyst Insights & forecasts

Buy100%
Hold0%
Sell0%

Based on information from 19 analysts.

Average price target$72.83

Earnings per share (EPS) forecast

Q4 • 25Q1 • 26Q2 • 26Q3 • 26
Actual-$0.45-$0.71-$1.44-$0.46
Expected-$0.45-$0.49-$0.55-$0.55
Surprise--44.90%-161.82%16.36%
BeatMissedMissedCurrent

Financial Performance

Q2 • 26Q3 • 26QoQ growth
Revenue$0M$0MNaN%
Net income$-159M$-51M-67.95%
Profit margin-∞%-∞%NaN%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

FAQs

01How much is a Definium Therapeutics, Inc. share?

Definium Therapeutics, Inc. shares are currently traded for undefined per share.

02How many shares does Definium Therapeutics, Inc. have?

Definium Therapeutics, Inc. currently has 137M shares.

03Does Definium Therapeutics, Inc. pay dividends?

No, Definium Therapeutics, Inc. doesn't pay dividends.

04What is Definium Therapeutics, Inc. 52 week high?

Definium Therapeutics, Inc. 52 week high is $49.70.

05What is Definium Therapeutics, Inc. 52 week low?

Definium Therapeutics, Inc. 52 week low is $10.53.

06What is the 200-day moving average of Definium Therapeutics, Inc.?

Definium Therapeutics, Inc. 200-day moving average is $30.61.

07Who is Definium Therapeutics, Inc. CEO?

The CEO of Definium Therapeutics, Inc. is Robert Barrow.

08How many employees Definium Therapeutics, Inc. has?

Definium Therapeutics, Inc. has 105 employees.

09What is the market cap of Definium Therapeutics, Inc.?

The market cap of Definium Therapeutics, Inc. is $4.04B.

10What is the P/E of Definium Therapeutics, Inc.?

The current P/E of Definium Therapeutics, Inc. is null.

11What is the EPS of Definium Therapeutics, Inc.?

The EPS of Definium Therapeutics, Inc. is -$2.92.

12What is the PEG Ratio of Definium Therapeutics, Inc.?

The PEG Ratio of Definium Therapeutics, Inc. is null.

13What do analysts say about Definium Therapeutics, Inc.?

According to the analysts Definium Therapeutics, Inc. is considered a buy.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.